When to Use Anthracyclines in Early Breast Cancer
SAN ANTONIO — Patients with early-stage, node-negative, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and a high risk for recurrence benefited more from adding adjuvant anthracyclines to taxane-based chemotherapy than from taxane-based chemotherapy alone, according to a post-hoc analysis of the TAILORx study…
Read More
0
